IDO1 inhibitors for cancer immunotherapy

Drugs of the Future

Volumn 41, Issue 9, 2016, Pages 553-559

  Alford, B ^a   Cox, K ^b   Soliman, H ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b LAKE ERIE COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

3 dioxygenase; Cancer; Epacadostat; GDC 0919; IDO1 inhibitors; Immunotherapy; Indoleamine 2; Indoximod

Indexed keywords

EPACADOSTAT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INDOXIMOD;

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; MOLECULAR BIOLOGY; PREDICTIVE VALUE;

EID: 84995616659     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2016.041.09.2526561     Document Type: Article

References (61)

1. Brunschwig, A. The efficacy of "Coley's toxin" in the treatment of sarcoma: An experimental study. Ann Surg 1939, 109(1): 109-13.
2. Lamm, D.L. Optimal BCG treatment of superficial bladder cancer as defined by American trials. Eur Urol 1992, 21(Suppl. 2): 12-6.
3. Sparano, J.A., Fisher, R.I., Sunderland, M. et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993, 11(10): 1969-77.
4. Vinay, D.S., Ryan, E.P., Pawelec, G. et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015, 35(Suppl.): S185-98.
5. Yamamoto, S., Hayaishi, O. Tryptophan pyrrolase of rabbit intestine. D-and L-tryptophan-cleaving enzyme or enzymes. J Biol Chem 1967, 242(22): 5260-6.
6. Batista, C.E., Juhasz, C., Muzik, O. et al. Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors. Mol Imaging Biol 2009, 11(6): 460-6.
7. Gao, Y.-F., Peng, R.-Q., Li, J. et al. The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer. J Transl Med 2009, 7: 71.
8. Munn, D.H., Sharma, M.D., Hou, D. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004, 114(2): 280-90.
9. Brandacher, G., Cakar, F., Winkler, C. et al. Non-invasive monitoring of kidney allograft rejection through IDO metabolism evaluation. Kidney Int 2007, 71(1): 60-7.
10. Chon, S.Y., Hassanain, H.H., Gupta, S.L. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gammainducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996, 271(29): 17247-52.
11. Spacek, M. Kynurenine in disease, with particular reference to cancer. Can Med Assoc J 1955, 73(3): 198-201.
12. Yoshida, R., Hayaishi, O. Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A 1978, 75(8): 3998-4000.
13. Yoshida, R., Urade, Y., Tokuda, M., Hayaishi, O. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc Natl Acad Sci U S A 1979, 76(8): 4084-6.
14. Yoshida, R., Imanishi, J., Oku, T., Kishida, T., Hayaishi, O. Induction of pulmonary indoleamine 2,3-dioxygenase by interferon. Proc Natl Acad Sci U S A 1981, 78(1): 129-32.
15. Munn, D.H., Zhou, M., Attwood, J.T. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281(5380): 1191-3.
16. Xu, H., Oriss, T.B., Fei, M. et al. Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci U S A 2008, 105(18): 6690-5.
17. Munn, D.H. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006, 18(2): 220-5.
18. Burke, F., Knowles, R.G., East, N., Balkwill, F.R. The role of indoleamine 2,3-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. Int J Cancer 1995, 60(1): 115-22.
19. Daubener, W., MacKenzie, C.R. IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol 1999, 467: 517-24.
20. Serbecic, N., Beutelspacher, S.C. Indoleamine 2,3-dioxygenase protects corneal endothelial cells from UV mediated damage. Exp Eye Res 2006, 82(3): 416-26.
21. Maneechotesuwan, K., Wamanuttajinda, V., Kasetsinsombat, K., Huabprasert, S., Yaikwawong, M., Barnes, P.J., Wongkajornsilp, A. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma. J Allergy Clin Immunol 2009, 123(1): 239-48.
22. Ciorba, M.A., Bettonville, E.E., McDonald, K.G., Metz, R., Prendergast, G.C., Newberry, R.D., Stenson, W.F. Induction of indoleamine 2,3 dioxygenase-1 by immunostimulatory-DNA limits severity of experimental colitis. J Immunol 2010, 184(7): 3907-16.
23. Gonzalo-Gil, E., Perez-Lorenzo, M.J., Galindo, M. et al. Human embryonic stem cell-derived mesenchymal stromal cells ameliorate collagen-induced arthritis by inducing host-derived indoleamine 2,3 dioxygenase. Arthritis Res Ther 2016, 18: 77.
24. Jia, Y., Wang, H., Wang, Y. et al. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer 2015, 137(5): 1095-106.
25. Chen, J.Y., Li, C.F., Kuo, C.C., Tsai, K.K., Hou, M.F., Hung, W.C. Cancer/ stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res 2014, 16(4): 410.
26. Folgiero, V., Goffredo, B.M., Filippini, P. et al. Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 2014, 5(8): 2052-64.
27. Choe, J.Y., Yun, J.Y., Jeon, Y.K. et al. Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: A retrospective cohort study. BMC Cancer 2014, 14: 335.
28. Mitsuka, K., Kawataki, T., Satoh, E., Asahara, T., Horikoshi, T., Kinouchi, H. Expression of indoleamine 2,3-dioxygenase and correlation with pathological malignancy in gliomas. Neurosurgery 2013, 72(6): 1031-8.
29. Friedman, K., Brodsky, A.S., Lu, S. et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol 2016, 29(5): 528-41.
30. Cheng, J.T., Deng, Y.N., Yi, H.M. et al. Hepatic carcinoma-associated fibroblasts induce IDO-producing regulatory dendritic cells through IL-6-mediated STAT3 activation. Oncogenesis 2016, 5: e198.
31. Ye, J., Liu, H., Hu, Y., Li, P., Zhang, G., Li, Y. Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch 2013, 462(1): 73-81.
32. Sorensen, R.B., Berge-Hansen, L., Junker, N. et al. The immune system strikes back: Cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One 2009, 4(9): e6910.
33. Sweis, R.F., Spranger, S., Bao, R., Paner, G.P., Stadler, W.M., Steinberg, G.D., Gajewski, T.F. Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res 2016, 4(7): 563-8.
34. Liu, H., Shen, Z., Wang, Z. et al. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci Rep 2016, 6: 21319.
35. Masaki, A., Ishida, T., Maeda, Y. et al. Prognostic significance of tryptophan catabolism in adult T-cell leukemia/lymphoma. Rinsho Ketsueki 2015, 56(11): 2295-304.
36. de Jong, R.A., Kema, I.P., Boerma, A. et al. Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol 2012, 126(3): 474-80.
37. Okamoto, A., Nikaido, T., Ochiai, K. et al. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 2005, 11(16): 6030-9.
38. Ou, X., Cai, S., Liu, P., Zeng, J., He, Y., Wu, X., Du, J. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol 2008, 134(5): 525-33.
39. Li, Y., Xu, J., Zou, H., Wang, C. 1-MT enhances potency of tumor cell lysatepulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of Tregs. J Huazhong Univ Sci Technolog Med Sci 2010, 30(3): 344-8.
40. Hou, D.Y., Muller, A.J., Sharma, M.D. et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007, 67(2): 792-801.
41. Metz, R., Rust, S., Duhadaway, J.B. et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 2012, 1(9): 1460-8.
42. Soliman, H.H., Minton, S.E., Han, H.S. et al. A phase I study of indoximod in patients with advanced malignancies. Oncotarget 2016, 7(16): 22928-38.
43. Soliman, H.H., Jackson, E., Neuger, T. et al. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget 2014, 5(18): 8136-46.
44. Tang, S.C., Montero, A., Munn, D., Link, C., Vahanian, N., Kennedy, E., Soliman, H. A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data. 38th Annu San Antonio Breast Cancer Symp (December 8-12, San Antonio) 2015, Abst P2-11-09.
45. Bahary, N., Garrido-Laguna, I., Wang-Gillam, A., Nyak-Kapoor, A., Kennedy, E., Vahanian, N.N., Link, C.J. Results of the phase Ib portion of a phase I/II trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreatic cancer. Gastrointest Cancers Symp (January 21-23, San Francisco) 2016, Abst 452.
46. Colman, H., Mott, F., Spira, A.I. et al. A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component. 51st Annu Meet Am Soc Clin Oncol (ASCO) (May 29-June 2, Chicago) 2015, Abst 2070.
47. Soliman, H.H., Minton, S.E., Ismail-Khan, R. et al. A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer. 37th Annu San Antonio Breast Cancer Symp (December 9-13, San Antonio) 2014, Abst P2-15-04.
48. Zakharia Y., Drabick, J.J., Khleif S., et al. Updates on phase 1b/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma. 52nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-7, Chicago) 2016, Abst 3075.
49. Koblish, H.K., Hansbury, M.J., Bowman, K.J. et al. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Mol Cancer Ther 2010, 9(2): 489-98.
50. Liu, X., Shin, N., Koblish, H.K. et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010, 115(17): 3520-30.
51. Spranger, S., Koblish, H.K., Horton, B., Scherle, P.A., Newton, R., Gajewski, T.F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014, 2: 3.
52. Jochems, C., Fantini, M., Fernando, R.I. et al. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells. Oncotarget 2016, 7(25): 37762.
53. Beatty, G.L., O'Dwyer, P.J., Clark, J. et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. 49th Annu Meet Am Soc Clin Oncol (ASCO) (May 31-June 4, Chicago) 2013, Abst 3025.
54. Gibney, G.T.H., O.; Gangadhar, T.C. et al. Preliminary results from a phase 1/2 study of INCB024360 combined with ipilimumab (ipi) in patients (pts) with melanoma. 50th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2014, Abst 3010.
55. Komrokji, R.S., Wei, S., Mailloux, A.W. et al. A phase II study to determine the safety and efficacy of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO) enzyme INCB024360 in patients with myelodysplastic syndromes. 56th Annu Meet Am Soc Hematol (December 6-9, San Francisco) 2014, Abst 4653.
56. Gangadhar, T.C., Hamid, O., Smith, D.C. et al. Preliminary results from a phase I/II study of epacadostat (INCB024360) in combination with pembrolizumab in patients with selected advanced cancers. 30th Annu Sci Meet Soc Immunother Cancer (SITC) (November 4-8, National Harbor) 2015, Abst O7.
57. Mautino, M.R., Jaipuri, F.A., Waldo, J. et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. 104th Annu Meet Am Assoc Cancer Res (AACR) (April 6-10, Washington, D.C.) 2013, Abst 491.
58. Mautino, M.R., Link, C.J., Vahanian, N.N. et al. Synergistic antitumor effects of combinatorial immune checkpoint inhibition with anti-PD-1/ PD-L antibodies and the IDO pathway inhibitors NLG-919 and indoximod in the context of active immunotherapy. 105th Annu Meet Am Assoc Cancer Res (AACR) (April 5-9, San Diego) 2014, Abst 5023.
59. Spahn, J., Peng, J., Lorenzana, E. et al. Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-L1 blockade versus anti-PD-L1 alone in preclinical tumor models. 30th Annu Sci Meet Soc Immunother Cancer (SITC) (November 4-8, National Harbor) 2015, Abst P317.
60. Nayak, A., Hao, Z., Sadek, R. et al. Phase 1a study of the safety, pharmacokinetics, and pharmacodynamics of GDC-0919 in patients with recurrent/ advanced solid tumors. Eur Cancer Congr (September 25-29, Vienna) 2015, Abst 346.
61. Mautino, M.R., Metz, R.A., Jaipuri, F. et al. Novel specific-and dual-tryptophan-2,3-dioxygenase (TDO) and indoleamine-2,3-dioxygenase (IDO) inhibitors for tumor immunotherapy. 105th Annu Meet Am Assoc Cancer Res (AACR) (April 5-9, San Diego) 2014, Abst 1633.